Home / Science / Cancer Fight at Inflection Point: Funding Threats Loom
Cancer Fight at Inflection Point: Funding Threats Loom
17 Sep
Summary
- 11 new cancer treatments approved since July 2025.
- Cancer mortality rate declined by 35% between 1991 and 2024.
- Research funding from NIH competitive awards has dropped this year.
Cancer research has seen remarkable advancements over the past year, achieving several landmark breakthroughs. Despite this progress, the field is confronting an "inflection point" due to mounting threats to research funding.
Eleven new treatments received FDA approval since July 2025. Furthermore, the cancer mortality rate has seen a substantial decline, falling by 35 percent between 1991 and 2024, indicating a winning trajectory in many cancer battles.
Emerging technologies like artificial intelligence are revolutionizing cancer care, aiding in image interpretation for screenings and drug design. Personalized mRNA vaccines and less invasive liquid biopsies also show immense promise for future treatments.
However, the American Association for Cancer Research highlights concerns over decreased funding from the National Institutes of Health. The association also expressed apprehension regarding proposals that could politicize and restrict scientific research, urging continued financial support to maintain momentum.
